Key Findings
At the EAACI 2026 annual congress, remarkably promising updated data were unveiled from Wave Life Sciences’ Phase 2 clinical trial for BW-20805, an investigational therapeutic for hereditary angioedema (HAE). This GalNAc-conjugated siRNA, designed to target plasma prekallikrein, demonstrated a dramatic reduction in HAE attack rates by 93% to 99% in adult patients with HAE types I/II, with an impressive 60% to 83% of participants maintaining a completely attack-free status.
Technical/Clinical Details
BW-20805 is a small interfering RNA (siRNA) specifically designed to target plasma prekallikrein, a key mediator in the pathophysiology of hereditary angioedema. SiRNAs function by degrading specific messenger RNA (mRNA) sequences, thereby inhibiting the expression of their corresponding proteins. BW-20805 is conjugated with a GalNAc (N-acetylgalactosamine) ligand, which enables its selective delivery to liver cells via the asialoglycoprotein receptor (ASGPR) expressed on their surface. As the liver is the primary site of prekallikrein production, this targeted delivery strategy is highly efficient. The updated Phase 2 data showed that treatment with BW-20805 not only significantly reduced the frequency of HAE attacks but also enabled a large proportion of patients to achieve complete attack suppression. The reported attack rate reduction of 93% to 99% is outstanding, and the fact that 60% to 83% of participants remained attack-free throughout the study period suggests a very potent and sustained therapeutic effect for HAE. An ongoing evaluation of a 6-month dosing regimen is particularly noteworthy, as its successful establishment could significantly reduce the treatment burden for patients.
Background & Context
Hereditary angioedema (HAE) is a rare genetic disorder caused by a deficiency or dysfunction of C1-inhibitor, a complement regulatory protein. This leads to an overproduction of bradykinin, resulting in recurrent episodes of swelling in the skin, gastrointestinal tract, and upper airways. Laryngeal edema can be life-threatening, and HAE patients require frequent attack management and prophylactic treatments. While existing HAE therapies include C1-inhibitor replacement and bradykinin B2 receptor antagonists, there is a clear demand for more convenient and long-lasting prophylactic options. RNAi therapeutics offer a particularly promising approach for genetic disorders like HAE, as they fundamentally suppress the expression of the causative gene. The success of BW-20805 underscores the vast potential of this modality in HAE treatment.
Strategic Significance & Outlook
The exceptionally strong data from the Phase 2 trial of BW-20805 have the potential to significantly alter the future landscape of hereditary angioedema treatment. The dramatic reduction in HAE attack rates and the high percentage of patients remaining attack-free suggest that this drug represents a major advance over existing therapies. The convenience of a 6-month dosing regimen, if established, would also greatly contribute to improved patient adherence. The expectation is for a larger Phase 3 clinical trial to commence, confirming the long-term efficacy and safety of BW-20805. If approved, BW-20805 could become a new standard for HAE prophylactic treatment, providing a transformative drug that dramatically improves patients’ quality of life.
Source: https://touchimmunology.com/insight/spotlight-on-hereditary-angioedema-at-eaaci-congress-2026/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments